Development of novel oligonucleotide therapeutics using functional liposomes for atrophic muscular disorder
| Project/Area Number |
16K20646
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Orthodontics/Pediatric dentistry
|
|---|
| Research Institution | The University of Tokushima |
|---|
Principal Investigator |
MORI Hiroyo 徳島大学, 病院, 助教 (80733914)
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 筋萎縮性疾患 / myostatin / siRNA / 歯学 |
|---|
| Outline of Final Research Achievements |
The present study was designed to assess the effectiveness of the co-delivery of myostatin-targeting siRNA (Mstn-siRNA) and ActRIIB-Fc into skeletal muscle. Inhibition of myostatin function by the combination of Mstn-siRNA and ActRIIB-Fc increased muscle weight and myofibril size in murine masseter muscle. Furthermore, myogenin mRNA expression was upregulated in the combination treatment group, while MuRF-1 and Atrogin-1 mRNA expression was downregulated compared to administration of each compound alone.
These findings suggest that co-administratioin of Mstn-siRNA and ActRIIB-Fc could be a useful treatment of atrophic muscular disease.
|
Report
(3 results)
Research Products
(6 results)
